Genmab - ADR Forecast, price target & analysts
Genmab - ADR Target price 2025 - Analyst rating & recommendation
Genmab - ADR Classifications & Recommendation:
Genmab - ADR Price Target
| Target Price | $30.59 |
| Price | $22.82 |
| Potential |
34.04%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Genmab - ADR 2026 .
The average Genmab - ADR target price is $30.59.
This is
34.04%
register free of charge
$45.00
97.20%
register free of charge
$14.90
34.72%
register free of charge
|
|
| A rating was issued by 24 analysts: 17 Analysts recommend Genmab - ADR to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Genmab - ADR stock has an average upside potential 2026 of
34.04%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.51 | 3.58 |
| 30.67% | 604.42% | |
| EBITDA Margin | 33.42% | 34.76% |
| 1.55% | 4.02% | |
| Net Margin | 36.44% | 2.72% |
| 37.93% | 92.54% |
21 Analysts have issued a sales forecast Genmab - ADR 2025 . The average Genmab - ADR sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Genmab - ADR EBITDA forecast 2025. The average Genmab - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Genmab - ADR Analysts have issued a net profit forecast 2025. The average Genmab - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.86 | 1.54 |
| 83.33% | 46.15% | |
| P/E | 14.86 | |
| EV/Sales | 3.82 |
19 Analysts have issued a Genmab - ADR forecast for earnings per share. The average Genmab - ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Genmab - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| REDBURN ATLANTIC |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| TRUIST SECURITIES |
Locked
➜
Locked
|
Locked | Mar 16 2025 |
| NYKREDIT MARKETS |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| DNB MARKETS |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| GUGGENHEIM SECURITIES LLC |
Locked
➜
Locked
|
Locked | Mar 09 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
REDBURN ATLANTIC:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
TRUIST SECURITIES:
Locked
➜
Locked
|
Mar 16 2025 |
|
Locked
NYKREDIT MARKETS:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
DNB MARKETS:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
GUGGENHEIM SECURITIES LLC:
Locked
➜
Locked
|
Mar 09 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
